Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Merck (MRK - Analyst Report) recently announced that it is taking its cholesterol management drug, Tredaptive (extended-release niacin/laropiprant), off the market. While Tredaptive (also known as Pelzont and Trevaclyn) is not approved in the US, it is available in 40 countries across the world and approved in 70 countries.

Merck’s decision was based on preliminary data from the long term safety study, HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events), and discussions with regulatory authorities.

Merck had announced disappointing results from the HPS2-THRIVE study in Dec 2012. Tredaptive failed to meet its primary endpoint in the study that compared Tredaptive plus statin therapy to statin therapy.

Results showed that adding Tredaptive to statin therapy did not lead to a significant reduction in the risk of major vascular events (a combination of coronary deaths, non-fatal heart attacks, strokes or revascularizations) compared to statin therapy. Moreover, the incidence of some types of non-fatal serious adverse events in the Tredaptive arm increased significantly.

Merck’s decision to take Tredaptive off the market is in line with the recommendation of the European Medicine Agency’s Pharmacovigilance Risk Assessment Committee (PRAC). The PRAC, which assessed available data related to safety concerns over Tredaptive, recommended that the marketing, supply and authorizations of Tredaptive, Pelzont and Trevaclyn should be suspended across the EU.

Our Take

The decision to suspend Tredaptive does not come as a surprise given the disappointing long-term safety data from the HPS-2 THRIVE study. Tredaptive sales were not significant (first nine month 2012 sales of the drug were $13 million) and its removal should not affect Merck’s top-line.

However, Tredaptive was one of the candidates in Merck’s pipeline slated for a US regulatory filing in 2013. Therefore, the suspension of the drug is a setback for the company’s pipeline efforts.

We currently have a Neutral recommendation on Merck, which carries a Zacks Rank #3 (Hold). Large-cap pharma companies that currently look better-positioned include Eli Lilly (LLY - Analyst Report), Johnson & Johnson (JNJ) and Novartis (NVS - Snapshot Report). All three are Zacks Rank #2 (Buy) stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%